Reduction of lipoxygenase products in psoriatic skin homogenates by QA 208-199.
D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D016859:Lipoxygenase Inhibitors; D009281:Naphthalenes / Q000494:pharmacology*; D011565:Psoriasis / Q000473:pathology*; D012867:Skin / Q000187:drug effects* / Q000378:metabolism
D006893:Hydroxyeicosatetraenoic Acids; D016859:Lipoxygenase Inhibitors; D009281:Naphthalenes; D007975:Leukotriene B4; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; C050439:N-hydroxy-N-methyl-7-propoxy-2-naphthaleneethanamine